– USA, MA – Minerva Neurosciences, Inc. (Nasdaq: NERV), today announced the appointment of Remy Luthringer, Ph.D., president and CSO of Minerva, to the additional post of CEO of the company, replacing Rogerio Vivaldi, MD, who will be leaving the company by mutual agreement effective November 30, 2014. Dr. Luthringer will also become a member of the Board of Directors of Minerva Neurosciences effective immediately.
“We are very pleased that Remy Luthringer will assume the additional role of CEO at Minerva and that he will also now be a member of our Board of Directors. His extensive drug development experience is an ideal fit to position us to advance our promising research platforms at this stage,” said Marc Beer, chairman of Minerva’s Board of Directors. “On behalf of the entire Board, I would also like to thank Dr. Vivaldi for his dedication and all his contributions to Minerva, including the preparation and execution of the company’s IPO earlier this year.”
About Dr. Luthringer
In his career, Dr. Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. He served as chief medical officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the chief executive officer of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a Ph.D. in neurosciences and clinical pharmacology.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva’s common stock is listed on the NASDAQ Global Market where it trades under the symbol “NERV.”
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
